Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotatug Vedotin in Advanced Biliary Tract Cancer
NCT07890311Phase 2Enrolling by invitation
- Sponsor
- Jiangmen Central Hospital
- Start
- Sep 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
A Phase 2 trial of becotatug vedotin in biliary tract cancer (BTC), sponsored by Jiangmen Central Hospital. Started Sep 2026; status: enrolling by invitation.
02
Drugs
becotatug vedotin
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07890311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07890311.